DOI:
10.1055/s-00000125
Senologie - Zeitschrift für Mammadiagnostik und -therapie
LinksClose Window
References
Cameron D, Piccart-Gebhart MJ, Gelber RD. et al.
11 yearsʼ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
Lancet 2017;
389: 1195-1205
We do not assume any responsibility for the contents of the web pages of other providers.